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Schistosoma 
mansoni in Family
5 Years after Safari 
To the Editor: Each year ≈350,000
Americans travel to Africa and
≈500,000 travel to Brazil and the Far
East, all schistosomiasis-endemic
regions. Data from the European
Network on Imported Infectious
Diseases Surveillance (TropNetEurop)
suggest that most schistosomiasis
cases imported to Europe are acquired
in Africa; 80% of new cases world-
wide occur in sub-Saharan Africa
(1,2). Travelers to Africa from the
United States are also at high risk for
infection.  Schistosoma mansoni has
the greatest impact on residents of dis-
ease-endemic areas who have high-
grade infection and progressive
hepatosplenic disease with portal
hypertension and its manifestations.
Most infected, short-term travelers
sustain a low-level of fluke infestation
with few symptoms, although serious
complications can occur. 
We report a 38-year-old American
man with ectopic S. mansoni fluke
migration that led to neural schistoso-
miasis. His symptoms prompted us to
test family members who had accom-
panied him on a trip to Kenya 5 years
earlier. The family members had been
unaware of the risk for schistosomia-
sis that the trip posed. Five years after
a Kenyan safari during which the
index patient visited northeastern
Lake Victoria and swam 1 afternoon,
vertigo, nausea, and nystagmus devel-
oped. The results of liver function
tests were normal and peripheral
blood showed no eosinophilia. Biopsy
of a large cerebellar lesion noted on
magnetic resonance imaging (MRI)
was diagnostic, yielding multiple S.
mansoni ova within large eosinophilic
granulomas, consistent with tumoral
neuroschistosomiasis. We tested 24 of
25 family members who had accom-
panied him to Kenya for schistosomi-
asis (Figure). All of the accompanying
family members, except 3 women,
had gone into the water. All members
were well, except an 8-year-old boy,
in whom granulomatous colitis had
developed after the trip.
Eighteen of 25 enzyme-linked
immunosorbent assays (ELISA) were
positive for S. mansoni infection,
including that of samples from the
index patient and the boy (Figure).
ELISA was performed on 18 samples
at the Centers for Disease Control and
Prevention (CDC) and 7 samples at
Focus Technologies. Both tests used
the same CDC-produced antigen, the
microsomal fraction of adult S. man-
soni fluke, which has both a sensitiv-
ity and specificity for S. mansoni of
99%. Confirmatory immunoblots
were performed at CDC on samples
from 19 of the 25 ELISA-tested fam-
ily members, with 1 discordant result,
a positive ELISA and negative S.
mansoni  and  hematobium  immuno-
blots. Three of 7 ELISA-negative
family members were the nonswim-
mers. Analyses of single stool speci-
mens from 7 family members, includ-
ing the index patient, and 1 rectal
biopsy sample were negative for ova.
Because of the high positivity rate,
praziquantel was prescribed for all 26
travelers. The index patient received
20 mg/kg of praziquantel twice daily
for 4 days and high-dose dexametha-
sone with subsequent 2-month taper;
his symptoms resolved over months.
An MRI 8 months after treatment
demonstrated minimal residual
inflammation. All other family mem-
bers received 20 mg/kg of praziquan-
tel twice in 1 day and tolerated it with-
out adverse events. Ten months after
treatment, the boy is growing after
years of an inflammatory colitis char-
acterized by hematochezia and
growth retardation. He continues to
have nonbloody diarrhea and consti-
pation.
We postulate that the mature fluke
pair migrated from the mesenteric
veins through Batson’s vertebral-
venous plexus to the cerebral veins at
the cerebellar level. There the female
expelled multiple ova into the cere-
bellum. An ensuing vigorous granulo-
matous response led to posterior fossa
mass effect and compression of
medullary nausea centers, which
resulted in the patient’s nausea, verti-
go, and nystagmus. Ectopic ovum
migration more commonly causes
neuroschistosomiasis; however, in
this case, multiple ova within 1 gran-
ulomatous mass suggest fluke-pair
migration rather than individual ovum
migration. Neuroschistosomiasis is
most commonly associated with
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Figure. Testing for Schistosoma mansoni infection among family members 5 years after
trip to Kenya. ELISA, enzyme-linked immunosorbent assay.See text for further description
of testing.LETTERS
S. japonicum, which has smaller ova.
In the literature, we found 16 other
case-patients with intracranial
tumoral  S. mansoni. Eight of the
patients demonstrated cerebellar
involvement, which suggests a com-
mon fluke migratory pathway (3–15).
Like our patient, 6 others were not
native to disease-endemic regions. 
This unsuspected case of neural
schistosomiasis illustrates the need
for detailed inquiry into every fresh-
water exposure by persons who have
traveled to schistosomiasis-endemic
regions. Adult Schistosoma flukes
generally survive in venules from 6 to
10 years but can survive <40 years;
therefore, remote travel history is rel-
evant. Examination of stool samples
for ova has been considered the stan-
dard method of diagnosing S. man-
soni and S. japonicum infection, and
urine examination is used to diagnose
S. haematobium. Multiple, fresh
morning specimens are ideal.
However, stool examination is not
likely to be as sensitive as current
immunologic assays for detecting
low levels of infection. Moreover, in
disease-nonendemic regions, opera-
tor variability may influence ova
detection. Among 13 recorded cases
of neurotumoral S. mansoni in which
stool specimens were examined, no
stool ova were found in 5 cases. In
our family cohort, among the 7
ELISA-positive members who sub-
mitted stool specimens, no examina-
tions performed at CDC demonstrat-
ed eggs (Figure). 
The ELISA uses a highly sensitive
and specific antigen for S. mansoni.
Because the sensitivity is less for S.
haematobium and S. japonicum, sub-
sequent species-specific immunoblots
are recommended based on travel his-
tory that suggests exposure to specific
species. Thus, we recommend ELISA,
immunoblot if applicable, and stool or
urine examination for travelers with
possible exposure in disease-endemic
regions. ELISA does not have the
same utility in persons native to dis-
ease-endemic regions because posi-
tivity is also consistent with earlier
infection. Stool or urine examination
is diagnostic in suspected immigrant
case-patients. 
In all cases, knowing that stool or
urine examination shows ova is valu-
able because repeat examination at 4
to 6 weeks can be used to monitor
treatment response. Because prazi-
quantel is well tolerated and effective,
empiric therapy among returning trav-
elers after possible exposure is rea-
sonable. However, diagnosing infec-
tion when possible and demonstrating
cleared infection after therapy are
more prudent approaches, particularly
as praziquantel resistance emerges
(16).
In conclusion, pretravel counseling
against freshwater exposure and post-
travel screening for schistosomiasis of
persons with any freshwater exposure
in disease-endemic regions are war-
ranted. As illustrated, the diagnosis of
schistosomiasis in a returned traveler
should prompt screening for infection
in fellow travelers. 
This work was presented in part at
the American Society of Tropical
Medicine and Hygiene 52nd annual meet-
ing, December 3–7, 2003, as late-breaking
abstract 2034, Philadelphia, PA. 
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Community-
associated
Methicillin-
resistant
Staphylococcus
aureus, Singapore
To the Editor: Community-asso-
ciated methicillin-resistant Staphylo-
coccus aureus (CA-MRSA) is an
emerging phenomenon that has been
reported from almost every continent
in the world (1–4). Such strains are
usually characterized by multisuscep-
tibility to non-β-lactam antimicrobial
drugs, production of Panton-Valentine
leukocidin (PVL), and presence of
staphylococcal chromosome cassette
mec (SCCmec) IVa, a novel smaller
variant of the methicillin-resistance
locus (5). The genetic backgrounds of
CA-MRSA strains from different
parts of the world are distinct and spe-
cific for each geographic region
(1–5). 
We conducted a study at our insti-
tution, a 1,600-bed adult acute-care,
tertiary-level public hospital, to deter-
mine evidence and the clinical and
molecular profile of CA-MRSA in
Singapore. We reviewed the microbi-
ology laboratory records at our institu-
tion for multidrug-susceptible MRSA
strains isolated from January 1, 2001,
to April 15, 2004. S. aureus was iden-
tified by colony morphologic features,
coagulation of citrated rabbit plasma
with EDTA (BBL Becton Dickinson
and Co., Cockeysville, MD, USA),
and production of clumping factor and
protein A(BactiStaph, Remel, Lenexa,
KS, USA). Methicillin resistance was
determined by susceptibility testing
and confirmed by latex agglutination
for penicillin binding protein-2a (6).
Multidrug-susceptible strains were
defined by susceptibility to cotrimoxa-
zole and gentamicin as determined by
the Kirby-Bauer disk diffusion method
following NCCLS guidelines (7).
The medical records of patients
infected by these MRSA were
reviewed, and strains were labeled
community-associated if they had
been isolated within 48 hours of hos-
pitalization from patients who had not
been in any hospital for >1 year.
Community-associated strains were
tested for PVL genes (8), and the
SCCmec  was typed by following a
previously described method (9).
Molecular typing was done by pulsed-
field gel electrophoresis (PFGE) with
restriction endonuclease SmaI and
multilocus sequence typing (10).
These strains were sent to the French
Reference Center for Staphylococci,
where genetic sequences encoding
accessory gene regulator (agr) sub-
types, enterotoxins, exfoliative toxins,
toxic-shock syndrome toxin-1,
hemolysins, and LukE-LukD leuko-
toxin were detected by polymerase
chain reaction (PCR)–based methods.
Comparisons with CA-MRSA strains
worldwide in terms of toxin profile
and PFGE patterns were also per-
formed in France; the latter was
achieved by using Taxotron software
(Institut Pasteur, Paris, France) to dig-
itize and analyze SmaI macrorestric-
tion patterns. 
Eight of 266 multidrug-susceptible
strains fulfilled the criteria for com-
munity acquisition, but only 5 of these
strains (corresponding to patients 1, 3,
and 6–8) had been archived. The
demographic and clinical data of the
patients are shown in the Table. Most
were young, healthy adults with cuta-
neous abscesses. Patient 1 had dia-
betes mellitus but had never been hos-
pitalized; he was the only patient with
severe bacteremic pneumonia. Patient
6 had early-stage endometrial cancer
resected in 2000 but had not attended
her follow-up appointments for >1
year before her hospitalization.
Patient 8 had traveled to Taipei,